United Technologies

United Therapeutics is a commercial-stage biotechnology company dedicated to developing innovative therapies for chronic and life-threatening conditions, with a primary focus on pulmonary arterial hypertension (PAH). The company's portfolio is anchored by its prostacyclin-based franchise, including Remodulin, Tyvaso, and Orenitram, as well as the oncology treatment Unituxin for neuroblastoma. Beyond pharmaceuticals, United Therapeutics is a pioneer in organ manufacturing and transplantation, investing heavily in technologies such as xenotransplantation, 3D bioprinting, and ex-vivo lung perfusion to address the global shortage of transplantable organs. Led by founder Martine Rothblatt, the company operates as a public benefit corporation, balancing its commitment to patient health with long-term shareholder value.